Get in the Game and Make Your Voice Heard! 60-Day Comment Period on Meaningful Use Stage 3 Rule Allows ASCRS•ASOA Members to Share their Feedback with CMS Directly

Despite opposition from ASCRS•ASOA, the medical community, and Congress, the Centers for Medicare and Medicaid Services (CMS) recently finalized its flawed Stage 3 of the EHR/Meaningful Use rule. Since the rule was proposed in April, 2015, ASCRS•ASOA has been working with the medical community to advocate for a delay of Stage 3, arguing the measure thresholds are too high—especially those for patient engagement measures. In addition, the program must be reformed to provide flexibility, address interoperability, and better reflect specialty practices before 2017 when it becomes part of the Merit-Based Incentive Payment System (MIPS), which was created under H.R. 2, the Medicare Access and CHIP Reauthorization Act (MACRA).

ASCRS•ASOA will continue to urge Congress to delay Stage 3 and will be submitting comments to CMS on the final rule, however, we cannot be successful without your help. ASCRS•ASOA members are encouraged to Get in the Game and submit their own comments to CMS. We need you to share how the Meaningful Use program is affecting you, your practice, and your patients, and the potential impact of the increased burden should Stage 3 proceed as planned.

Please visit Regulations.gov to submit your comments directly to CMS.

The deadline for submitting comments is December 15, 2015.

Tips for composing your message:

  • Identify yourself as an ophthalmologist or practice administrator;
  • Include how long you have participated in the Meaningful Use program;
  • Describe how your practice has been impacted by Meaningful Use; have you had to develop specific workflows or processes just to achieve certain measures, such as signing patients up for your portal?
  • Meaningful Use was intended to improve patient care. Include to what extent you have noticed that it has or has not; do the measures you are working to meet adequately reflect your practice and patient population?
  • Include any negative consequences your practice has experienced due to Meaningful Use; and
  • Describe how the increased thresholds in Stage 3 would be onerous to meet.

Do not hesitate to include anecdotes or specific examples from your practice that demonstrate how the program affects your practice.

Submit your comments now!

Visit ASCRS’ website for additional information on Stage 3 of Meaningful Use.

If you have questions or need assistance, please contact Allison Madson, manager of PAC and grassroots, at amadson@ascrs.org or 703-591-2220.